TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Blinded, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) in the Treatment of Iron Deficient Patients With Fibromyalgia
Brief Summary: This study investigates the efficacy and safety of an IV iron Injectafer in the treatment of iron deficient patients with fibromyalgia. Eligible subjects will be randomized in a 1:1 ratio to receive Injectafer or Placebo on days 0 and 5. All treated subjects will be followed for efficacy and safety for 42 days.


Options:
A: Arm Label: Injectafer; Type: EXPERIMENTAL; Interventions: Drug: Injectafer | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Injectafer; Assigned to Arm(s): Injectafer | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: CMS - placebo first; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Venesection, Drug: Iron sucrose, Drug: Normal saline | Arm Label: CMS - iron; Type: EXPERIMENTAL; Interventions: Procedure: Venesection, Drug: Iron sucrose, Drug: Normal saline | Arm Label: SLR - placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Arm Label: SLR - iron; Type: EXPERIMENTAL; Interventions: Drug: Iron sucrose | Intervention Type: DRUG; Name: Iron sucrose; Assigned to Arm(s): SLR - iron | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): SLR - placebo | Intervention Type: PROCEDURE; Name: Venesection; Assigned to Arm(s): CMS - iron, CMS - placebo first | Intervention Type: DRUG; Name: Iron sucrose; Assigned to Arm(s): CMS - iron, CMS - placebo first | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): CMS - iron, CMS - placebo first
C: Arm Label: Single oral iron supplement per day (120 mg); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Single oral iron dose of 120 mg per day for 3 consecutive days | Arm Label: B.i.d. oral iron supplement (2x 60 mg); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days | Intervention Type: DIETARY_SUPPLEMENT; Name: Single oral iron dose of 120 mg per day for 3 consecutive days; Assigned to Arm(s): Single oral iron supplement per day (120 mg) | Intervention Type: DIETARY_SUPPLEMENT; Name: Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days; Assigned to Arm(s): B.i.d. oral iron supplement (2x 60 mg)
D: Arm Label: Iron Dextran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Iron dextran | Arm Label: Iron Sucrose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Iron sucrose | Intervention Type: DRUG; Name: Iron dextran; Assigned to Arm(s): Iron Dextran | Intervention Type: DRUG; Name: Iron sucrose; Assigned to Arm(s): Iron Sucrose

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial Of Intensive Versus Minimal Surveillance Of Patients With Resected Dukes B2-C Colorectal Carcinoma
Brief Summary: Dukes B2-C colorectal cancer patients who had no evidence of disease at the end of their front line treatment (surgery and adjuvant radio-chemotherapy, if indicated) are eligible for the trial and randomized to two different surveillance programs. These programs differ greatly in the frequency of diagnostic imaging. They have similar schedules of physical examinations and carcinoembryonic antigen (CEA) assessments. Patients will receive baseline and yearly health-related quality of life (HR-QoL) questionnaires. Primary outcomes are overall survival and QoL.


Options:
A: Arm Label: minimal surveillance; Type: OTHER; Interventions: Other: surveillance program after completion of primary treatment | Arm Label: intensive surveillance; Type: OTHER; Interventions: Other: surveillance program after completion of primary treatment | Intervention Type: OTHER; Name: surveillance program after completion of primary treatment; Assigned to Arm(s): intensive surveillance, minimal surveillance
B: Arm Label: Patient Directed; Type: OTHER; Interventions: Other: 'My Care Plan' | Arm Label: Clinician Directed; Type: OTHER; Interventions: Other: 'Survivorship Care Plan Builder' | Intervention Type: OTHER; Name: 'My Care Plan'; Assigned to Arm(s): Patient Directed | Intervention Type: OTHER; Name: 'Survivorship Care Plan Builder'; Assigned to Arm(s): Clinician Directed
C: Arm Label: Survivorship Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Survivorship Intervention | Arm Label: Facing Forward; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Facing Forward | Intervention Type: BEHAVIORAL; Name: Survivorship Intervention; Assigned to Arm(s): Survivorship Intervention | Intervention Type: BEHAVIORAL; Name: Facing Forward; Assigned to Arm(s): Facing Forward
D: Arm Label: IVR Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive Voice Response Symptom Management, Behavioral: Tailored Newsletters | Arm Label: Enhanced Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Interactive Voice Response Symptom Management; Assigned to Arm(s): IVR Intervention | Intervention Type: BEHAVIORAL; Name: Tailored Newsletters; Assigned to Arm(s): IVR Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Brief Summary: Available data suggest that low dose aspirin may be a safe, widely available and inexpensive intervention that may significantly reduce the risk of preterm birth. However, this possibility needs to be proven in a properly designed randomized controlled trial (RCT) with preterm birth as the primary outcome. Such a clinical trial in a racially, ethnically and geographically diverse population could best be accomplished by the established infrastructure of the Global Network for Women's and Children's Health Research (GN).


Options:
A: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: acetylsalicylic-acid (aspirin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic acid | Intervention Type: DRUG; Name: acetylsalicylic-acid (aspirin); Assigned to Arm(s): Aspirin | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Placebo
B: Arm Label: Treatment Arm; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Treatment Arm | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Control Arm
C: Arm Label: Routine low-dose aspirin; Type: EXPERIMENTAL; Interventions: Drug: Low dose aspirin | Arm Label: No aspirin; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Test-indicated low-dose aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose aspirin | Intervention Type: DRUG; Name: Low dose aspirin; Assigned to Arm(s): Routine low-dose aspirin, Test-indicated low-dose aspirin
D: Arm Label: Intervention Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose aspirin | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Low dose aspirin; Assigned to Arm(s): Intervention Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ALFoNS - Growth and Metabolism in Infants Fed Protein-reduced, Alpha-lactalbumin Enriched Formula Compared to Breastfed Infants
Brief Summary: Formula composition is developed to resemble breast milk as close as possible, but there are still considerable differences between formula and breast milk composition, probably resulting in higher risk of overweight in childhood and higher incidence of infections in formula-fed infants. Protein levels are still higher and constituents such as alpha-lactalbumin lower in formula than in breast milk. By adding more alpha-lactalbumin to formula, rich in tryptophan, the resulting amino acid composition will allow further reduction of protein in formula. The investigators intend to include 320 infants, where 80 will be exclusively breastfed and the remainder assigned in a double blind, controlled, randomized manner to one of three formula groups; two experimental, protein reduced formula with two different levels of alpha-lactalbumin and one group given standard infant formula. The intervention period is from 4-8 weeks until 6 months of age. The infants will be followed by growth parameters, blood-, urine- and fecal biomarkers and health parameters until 5 years of age. The experimental formula will possibly result in growth, metabolism and gut microbiota as well as health parameters more similar to those of breastfed infants


Options:
A: Intervention Type: DRUG; Name: changing of fortifier; Assigned to Arm(s): N/A
B: Arm Label: parenteral nutrition solution; Type: OTHER; Interventions: Drug: Ped3CB | Intervention Type: DRUG; Name: Ped3CB; Assigned to Arm(s): parenteral nutrition solution
C: Arm Label: Lower protein formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lower protein formula; Higher protein formula | Arm Label: Higher protein formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Lower protein formula; Higher protein formula | Arm Label: Breastfed reference group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lower protein formula; Higher protein formula; Assigned to Arm(s): Higher protein formula, Lower protein formula
D: Arm Label: Standard infant formula; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Standard infant formula | Arm Label: Protein-reduced whey formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Protein-reduced whey formula | Arm Label: Protein-reduced α-lactalbumin formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Protein-reduced α-lactalbumin formula | Arm Label: Breast-feeding; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Protein-reduced α-lactalbumin formula; Assigned to Arm(s): Protein-reduced α-lactalbumin formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Protein-reduced whey formula; Assigned to Arm(s): Protein-reduced whey formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Standard infant formula; Assigned to Arm(s): Standard infant formula

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Frequently Asked Questions as an Help to Improve the Information of ICU Patients' Families.
Brief Summary: The intervention consists of the delivery of a list of 21 questions to the relative of each patient admitted in ICU, intubated and mechanically ventilated during the first 48 hours of the stay. A formal interview is scheduled for relatives at Day 3 of inclusion. The information comprehension at Day 5 (± 1) will be compared between families that received the list of "FAQ" and families that received information as usual (without providing the list of FAQ


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Decision support skills building Intervention | Intervention Type: BEHAVIORAL; Name: Decision support skills building Intervention; Assigned to Arm(s): 1
B: Arm Label: Group I (web-based legacy intervention); Type: EXPERIMENTAL; Interventions: Other: Internet-Based Intervention, Other: Quality-of-Life Assessment, Other: Questionnaire Administration | Arm Label: Group II (standard of care); Type: ACTIVE_COMPARATOR; Interventions: Other: Best Practice, Other: Quality-of-Life Assessment, Other: Questionnaire Administration | Intervention Type: OTHER; Name: Internet-Based Intervention; Assigned to Arm(s): Group I (web-based legacy intervention) | Intervention Type: OTHER; Name: Best Practice; Assigned to Arm(s): Group II (standard of care) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Group I (web-based legacy intervention), Group II (standard of care) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Group I (web-based legacy intervention), Group II (standard of care)
C: Arm Label: video decision aid; Type: EXPERIMENTAL; Interventions: Behavioral: video decision aid | Arm Label: Usual Care -- Verbal Description Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: video decision aid; Assigned to Arm(s): video decision aid
D: Arm Label: families that received the list of "FAQ"; Type: N/A; Interventions: Other: list of "FAQ" | Arm Label: families that received information as usual; Type: N/A; Interventions: Other: list of "FAQ" | Intervention Type: OTHER; Name: list of "FAQ"; Assigned to Arm(s): families that received information as usual, families that received the list of "FAQ"

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Carbetocin Versus Oxytocin in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally: A Randomised Controlled Trial
Brief Summary: 200 women will be randomly divided into 2 equal groups using computer generated random numbers. Group 1 will receive Carbetocin 100 µgm (Pabal® Ferring, UK) and group 2 will receive ergometrine 0.5mg (methergin®, Novartis, Switzerland).


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Community Engagement, Device: PIERS on the Move mHealth decision aid, Drug: Magnesium Sulfate, Drug: Methyldopa | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Community Engagement; Assigned to Arm(s): Intervention | Intervention Type: DEVICE; Name: PIERS on the Move mHealth decision aid; Assigned to Arm(s): Intervention | Intervention Type: DRUG; Name: Magnesium Sulfate; Assigned to Arm(s): Intervention | Intervention Type: DRUG; Name: Methyldopa; Assigned to Arm(s): Intervention
B: Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): misoprostol
C: Arm Label: Primary prevention; Type: OTHER; Interventions: Drug: Misoprostol | Arm Label: Secondary Prevention; Type: OTHER; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Secondary Prevention | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Primary prevention
D: Arm Label: Carbetocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Ergometrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ergometrine | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin | Intervention Type: DRUG; Name: Ergometrine; Assigned to Arm(s): Ergometrine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rifapentine-containing Treatment Shortening Regimens for Pulmonary Tuberculosis: A Randomized, Open-label, Controlled Phase 3 Clinical Trial. TBTC Study 31, ACTG Study A5349
Brief Summary: The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a standard six-month regimen for treatment of pulmonary tuberculosis (TB). All three regimens are administered daily, seven days each week, with direct observation of each dose by a health-care worker at least five of the seven days of each week.

The standard six-month regimen is two months of isoniazid, rifampin, ethambutol, and pyrazinamide followed by four months of isoniazid and rifampin.

The first short regimen is a single substitution of rifapentine for rifampin: two months of isoniazid, rifapentine, ethambutol, and pyrazinamide, followed by two months of isoniazid and rifapentine.

The second short regimen is a double substitution of rifapentine for rifampin and moxifloxacin for ethambutol: two months of isoniazid, rifapentine, moxifloxacin, and pyrazinamide, followed by two months of isoniazid, rifapentine, and moxifloxacin.

Target enrollment is 2500 participants. Each study participant will remain in the study for 18 months in order to include at least 12 months of evaluation of whether the participant's TB recurs.


Options:
A: Arm Label: Case Detection Group; Type: N/A; Interventions: Diagnostic Test: Truenat MTB | Arm Label: Drug Resistant TB Group; Type: N/A; Interventions: Diagnostic Test: Truenat MTB | Intervention Type: DIAGNOSTIC_TEST; Name: Truenat MTB; Assigned to Arm(s): Case Detection Group, Drug Resistant TB Group
B: Arm Label: Centralised Xpert®Ultra testing; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Xpert Ultra Point of Care testing; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: Xpert Ultra Point of Care testing | Intervention Type: DIAGNOSTIC_TEST; Name: Xpert Ultra Point of Care testing; Assigned to Arm(s): Xpert Ultra Point of Care testing
C: Arm Label: Regimen 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: control | Arm Label: Regimen 2; Type: EXPERIMENTAL; Interventions: Drug: rifapentine | Arm Label: Regimen 3; Type: EXPERIMENTAL; Interventions: Drug: rifapentine and moxifloxacin | Intervention Type: DRUG; Name: rifapentine; Assigned to Arm(s): Regimen 2 | Intervention Type: DRUG; Name: rifapentine and moxifloxacin; Assigned to Arm(s): Regimen 3 | Intervention Type: DRUG; Name: control; Assigned to Arm(s): Regimen 1
D: Arm Label: Case detection group; Type: N/A; Interventions: Device: Investigational Xpert DST test | Arm Label: Drug resistance risk group; Type: N/A; Interventions: Device: Investigational Xpert DST test | Intervention Type: DEVICE; Name: Investigational Xpert DST test; Assigned to Arm(s): Case detection group, Drug resistance risk group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adductor Canal Block and Functional Recovery After Total Knee Arthroplasty. A Double-Blind, Randomized Controlled Trial
Brief Summary: This study aims to compare the functional recovery of patients undergoing Total Knee Arthroplasty based on the administration of an adductor canal block during their anesthesia treatment


Options:
A: Arm Label: Arm RP; Type: OTHER; Interventions: Drug: Ropivacaine, Drug: Saline | Arm Label: Arm PR; Type: OTHER; Interventions: Drug: Ropivacaine, Drug: Saline | Intervention Type: DRUG; Name: Ropivacaine; Assigned to Arm(s): Arm PR, Arm RP | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Arm PR, Arm RP
B: Arm Label: Adductor-Canal-Blockade; Type: EXPERIMENTAL; Interventions: Procedure: Adductor-Canal-Blockade | Arm Label: Femoral Nerve Block; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Femoral Nerve Block | Intervention Type: PROCEDURE; Name: Adductor-Canal-Blockade; Assigned to Arm(s): Adductor-Canal-Blockade | Intervention Type: PROCEDURE; Name: Femoral Nerve Block; Assigned to Arm(s): Femoral Nerve Block
C: Arm Label: Local Inflitration Only; Type: PLACEBO_COMPARATOR; Interventions: Drug: Local Infiltration | Arm Label: Adductor Canal Block; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adductor Canal Block | Arm Label: Adductor Canal Block with Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adductor Canal Block with Morphine | Intervention Type: DRUG; Name: Adductor Canal Block; Assigned to Arm(s): Adductor Canal Block | Intervention Type: DRUG; Name: Adductor Canal Block with Morphine; Assigned to Arm(s): Adductor Canal Block with Morphine | Intervention Type: DRUG; Name: Local Infiltration; Assigned to Arm(s): Local Inflitration Only
D: Arm Label: Adductor-Canal-Block, Ropivacain; Type: EXPERIMENTAL; Interventions: Procedure: Ropivacain | Arm Label: Adductor Canal Block, Placebo (saline); Type: PLACEBO_COMPARATOR; Interventions: Procedure: Saline | Intervention Type: PROCEDURE; Name: Ropivacain; Assigned to Arm(s): Adductor-Canal-Block, Ropivacain | Intervention Type: PROCEDURE; Name: Saline; Assigned to Arm(s): Adductor Canal Block, Placebo (saline)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Study of Adipokines and Calorie Restriction in Multiple Sclerosis Patients
Brief Summary: The investigators hypothesize that adipokine (soluble molecules produced by the adipose tissue) levels are altered in MS compared to control subjects. Additionally, the investigators hypothesize that calorie restriction (CR) will improve clinical recovery from an MS relapse, ameliorate the adipokine and metabolic-inflammatory profile in MS, and enhance immune-regulatory mechanisms.

This is a pilot study to determine the effects of CR in MS patients during an acute MS relapse (Acute CR phase) and for 6 months afterwards (Chronic CR phase). Calorie restriction will be achieved by following a regimen of alternate day fasting. The investigators will evaluate clinical outcomes and blood biomarkers at different time points.


Options:
A: Arm Label: Time restricted feeding; Type: EXPERIMENTAL; Interventions: Other: Time restricted feeding | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Time restricted feeding; Assigned to Arm(s): Time restricted feeding
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Calorie restriction; Type: EXPERIMENTAL; Interventions: Other: Calorie restriction | Intervention Type: OTHER; Name: Calorie restriction; Assigned to Arm(s): Calorie restriction
C: Arm Label: Normal Feeding; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Time Restricted Feeding; Type: EXPERIMENTAL; Interventions: Behavioral: Time Restricted Feeding | Intervention Type: BEHAVIORAL; Name: Time Restricted Feeding; Assigned to Arm(s): Time Restricted Feeding
D: Arm Label: Time-Restricted Feeding (early in the day eating); Type: EXPERIMENTAL; Interventions: Other: Time-Restricted Feeding | Arm Label: Grazing; Type: PLACEBO_COMPARATOR; Interventions: Other: Grazing | Intervention Type: OTHER; Name: Time-Restricted Feeding; Assigned to Arm(s): Time-Restricted Feeding (early in the day eating) | Intervention Type: OTHER; Name: Grazing; Assigned to Arm(s): Grazing

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Short-term Effects of Chest Physiotherapy on Ventilation Inhomogeneity in Non-CF Bronchiectasis
Brief Summary: This study will investigate the effects of on technique of chest physiotherapy on pulmonary function. Effects of pulmonary function will be measured by the spirometry, body plethysmography and by the multiple breath nitrogen washout technique.


Options:
A: Arm Label: 1. Exercise testing and self drainage session; Type: EXPERIMENTAL; Interventions: Procedure: Chest physiotherapy | Arm Label: 2. Chest physiotherapy (CP) session; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Chest physiotherapy | Intervention Type: PROCEDURE; Name: Chest physiotherapy; Assigned to Arm(s): 1. Exercise testing and self drainage session, 2. Chest physiotherapy (CP) session
B: Arm Label: Autogenic drainage; Type: OTHER; Interventions: Other: Autogenic drainage | Intervention Type: OTHER; Name: Autogenic drainage; Assigned to Arm(s): Autogenic drainage
C: Arm Label: Normal airway clearance; Type: EXPERIMENTAL; Interventions: Other: Airway Clearance Techniques | Arm Label: Non-Invasive Ventilation; Type: EXPERIMENTAL; Interventions: Other: Airway Clearance Techniques | Intervention Type: OTHER; Name: Airway Clearance Techniques; Assigned to Arm(s): Non-Invasive Ventilation, Normal airway clearance
D: Arm Label: USUAL CARE; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: INHALATION WITH PEP DEVICE; Type: ACTIVE_COMPARATOR; Interventions: Device: INHALATION WITH PEP DEVICE (Acapella Duet) | Intervention Type: DEVICE; Name: INHALATION WITH PEP DEVICE (Acapella Duet); Assigned to Arm(s): INHALATION WITH PEP DEVICE

Answer: B